Company / Return on Equity (ROE)
Solid Biosciences Inc. Return on Equity (ROE) History
FY2019-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-42.4%
FY2022
5-year range
-93.4% / -41.6%
FY2019-FY2022
Trend
+52.2%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Solid Biosciences Inc. reports negative total equity of -42.4% in FY2022. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-42.4% in FY2022 with a 3-year CAGR of -0.8%.
Improved from -93.4% to -42.4% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -0.8pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2022, return on equity (roe) increased 52.2% year-over-year.
Company context
Key Data Points
- Altman Z-Score 1.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2022 | -42.4% | +52.2% |
| FY2021 | -88.8% | +5.0% |
| FY2020 | -93.4% | -124.5% |
| FY2019 | -41.6% | - |
| FY2018 | - | - |
As of FY2022 · SEC 10-K · Updated Jun 28, 2026